On Nov 09, major Wall Street analysts update their ratings for $Moderna (MRNA.US)$, with price targets ranging from $60 to $112.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $70.
Goldman Sachs analyst Salveen Richter maintains with a buy rating, and adjusts the target price from $139 to $112.
BofA Securities analyst Alec Stranahan maintains with a hold rating, and adjusts the target price from $110 to $90.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $125 to $111.
Evercore analyst Cory Kasimov maintains with a hold rating, and maintains the target price at $60.
Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:
Moderna's Q3 SpikeVax revenue exceeded expectations and the company maintained its previous guidance. Despite anticipating the approval of two additional vaccines, the company presented a prudent projection for the year 2025.
Moderna's recent quarterly performance surpassed expectations, mainly due to an earlier commencement of the vaccination season compared to the previous year. Nonetheless, the company has moderated its vaccination rate outlook for the year, shifting from 'flat' in comparison to last year to a potential decline of up to 10%. Additionally, while revenue guidance for the year remains unchanged, expectations have been adjusted to conclude towards the lower end of the projected range.
Here are the latest investment ratings and price targets for $Moderna (MRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月9日，多家华尔街大行更新了$Moderna (MRNA.US)$的评级，目标价介于60美元至112美元。
摩根士丹利分析师Terence Flynn维持持有评级，维持目标价70美元。
高盛集团分析师Salveen Richter维持买入评级，并将目标价从139美元下调至112美元。
美银证券分析师Alec Stranahan维持持有评级，并将目标价从110美元下调至90美元。
巴克莱银行分析师Gena Wang维持买入评级，并将目标价从125美元下调至111美元。
Evercore分析师Cory Kasimov维持持有评级，维持目标价60美元。
此外，综合报道，$Moderna (MRNA.US)$近期主要分析师观点如下：
以下为今日6位分析师对$Moderna (MRNA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
